in this issue
Regions :: Western Europe :: Switzerland
Lonza signs agreement with Index Ventures for development and manufacture of biologics
12:16 AM MST | January 14, 2014 | Deepti Ramesh
Lonza and Index Ventures, a leading venture capital investment firm, have signed an exclusive five-year agreement for process development and cGMP production for all biological products in the portfolio of companies where Index Ventures is the major investor. Additional development and manufacturing projects will be added to the product list over the course of the agreement as future investments are made by Index Ventures, Lonza...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee